Taking stock of the drug industry, from the lab to the medicine chestApril 14, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Alex Brandon/AP STAT+ | Trump administration launches probe into pharmaceutical imports The so-called 232 investigation actually began on April 1 and encompasses not only medicines, but also active pharmaceutical ingredients. By Ed Silverman STAT+ | Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity Pfizer said in a press release that an asymptomatic volunteer in the company's studies experienced "potential drug-induced liver injury." By Matthew Herper STAT+ | Canada advances an antitrust probe into Express Scripts over 'patient steering' and pharmacy fees This marks the latest instance in which a federal government antitrust regulator has moved to take action over PBM business practices. By Ed Silverman Jeff Roberson/AP STAT+ | Tennessee officials find Express Scripts violated law governing commercial pharmacy claims The audit found Express Scripts failed to properly reimburse pharmacies and favored its own specialty pharmacy operations. By Ed Silverman STAT+ | Verve gene-editing therapy lowers cholesterol without serious side effects in early study Initial Phase 1 data show that a single infusion of Verve-102 led to greater decreases in "bad" LDL cholesterol with higher doses. By Elaine Chen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments